CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN) today announced the resignation of Howard Pien from the Company’s Board of Directors. Mr. Pien recently accepted the position of president and chief executive officer of Medarex, Inc. Since ImmunoGen and Medarex both develop antibody-based anticancer therapeutics, Mr. Pien’s new role with Medarex creates a conflict of interest with his role as a Director of ImmunoGen. The Company has initiated a search to replace Mr. Pien on its Board.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company’s proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing – huN901-DM1 and huC242-DM4. Three anticancer compounds are in clinical testing through ImmunoGen’s collaborations with other companies – AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-DM1, in development by Genentech. Multiple compounds are in research/preclinical development.
Contacts
Investors:
ImmunoGen, Inc. Carol Hausner, 617-995-2500 Executive Director, Investor Relations and Corporate Communications info@immunogen.com or
Media:
KMorrisPR Kathryn Morris, 845-635-9828 Kathryn@kmorrispr.com
